Dyadic, Cygnus announce partnership to provide C1 HCP ELISA Assay

Dyadic International (DYAI) and Cygnus Technologies, part of Maravai LifeSciences (MRVI), announced a strategic partnership for the quantification of Host Cell Proteins from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica. Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers. Mark Emalfarb, CEO of Dyadic, commented, “I can’t stress enough the significance of our partnership with Cygnus, the C1 HCP assay provides adopters of our C1 microbial production platform a solution for testing C1 HCP impurity during product lot release testing, thereby enhancing the quality assurance process in biomanufacturing. The biopharmaceutical industry demands a fast, efficient, and reliable method for monitoring HCPs during manufacturing to ensure the delivery of safe and efficacious products in a cost-effective manner. Our collaboration with Cygnus resulted in the development of a first-in-class C1 HCP ELISA assay, making a significant step toward greater adoption of the C1 technology globally.”